News Releases
-
Jan 22, 2020SUBA™-Itraconazole to be Tested in Combination with Standard of Care Chemotherapy for Metastatic Castrate Resistant Prostate Cancer
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous...
-
Nov 25, 2019SUBA™-Itraconazole to be Tested in Combination with Standard of Care Chemotherapy for Metastatic Castrate Resistant Prostate Cancer
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous...
-
Oct 31, 2019Industry Veteran Brings 30 Years of Experience to Support INTI's Biopharmaceutical and Corporate Programs
INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit the progression of...
-
Aug 19, 2019New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™-Itraconazole, Inhibiting the Hedgehog Signaling Pathway
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit the progression of...
-
May 29, 2019New method of use claims in lung cancer enhance HedgePath’s intellectual property estate relating to SUBA‐Itraconazole
TAMPA, FL, MAY 29, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to...
-
May 6, 2019Twenty new claims for use of itraconazole as a means of Hedgehog pathway inhibition Patent expected to issue coincident with HedgePath’s 2019 efforts to clear IND for SUBA®-Itraconazole for the treatment of prostate cancer
TAMPA, FL, MAY 6, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative...
-
Apr 15, 2019
Tampa, FL, April 15, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative...
-
Mar 7, 2019
Corporate Highlights: Secured the potential for up to $5 million in new funding ($1.5 million of which has been funded to date) and further secured a 9% royalty on future U.S. sales of...
-
Dec 17, 2018HPPI to transfer SUBA-Itraconazole BCCNS clinical program to Mayne Pharma in consideration of up to $5 million in new funding from Mayne Pharma and a 9% royalty on future SUBA-Itraconazole BCCNS sales in the U.S. With new funding, HPPI to move towards IND filing during 2019 and recruitment to initiate human trials for SUBA-Itraconazole Prostate HPPI also to pursue expansion of product candidate pipeline with non-SUBA itraconazole analogue technology with University of Connecticut
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (December 17, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) announced today that it has entered into a revised Supply and License Agreement (SLA)...
-
Aug 6, 2018FDA has confirmed HPPI’s clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (August 6, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Jul 19, 2018Access to UCONN’s technology could create the potential for HPPI to expand its pipeline of clinical stage itraconazole-based cancer treatments
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (July 19, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Jul 9, 2018Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program HPPI to meet with FDA this month to discuss proposed 2018 NDA filing
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (July 9, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Jun 5, 2018HPPI preparing patient dossiers for a July face-to-face meeting with FDA with the goal of filing an NDA later in 2018 Additional promising clinical trial data also announced
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (June 5, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
May 21, 2018HPPI’s patent portfolio expands again with claims covering treatment of any non-cancerous proliferation disorders with itraconazole, the active ingredient in HPPI’s current and anticipated future product candidates
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (May 21, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
May 14, 2018HPPI’s patent portfolio expands with claims covering treatment of both hematologic and nonhematologic cancers with itraconazole, the active ingredient in HPPI’s current and anticipated future product candidates
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (May 14, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Jan 11, 2018HPPI receives three tranche preferred stock and warrant funding, with $2.4 million upfront, $1.6 million by mid-2018, and an additional $1 million by year end if BCCNS NDA is accepted
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (January 11, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Oct 30, 2017Positive outcomes continue to be observed in open label trial; Company will lock database to complete clinical study report in anticipation of Pre-NDA Meeting with FDA
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (October 30, 2017) – HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Jul 25, 2017HPPI to proceed with streamlined 505(b)(2) regulatory pathway for SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma Nevus Syndrome
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (July 25, 2017) – HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
May 30, 201735 subjects with Basal Cell Carcinoma Nevus Syndrome in ongoing Phase 2(b) trial have a median time on study of 32 weeks of dosing with SUBA™-Itraconazole
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (May 30, 2017) – HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Oct 20, 201618 subjects with Basal Cell Carcinoma Nevus Syndrome who had 231 surgically eligible tumors complete 16 weeks of dosing with SUBA™-Itraconazole
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (October 20, 2016) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Sep 12, 2016Presentation to be held Tuesday, September 13, 2016 at 3pm EDT Lotte New York Palace Hotel
TAMPA, FLORIDA – (September 12, 2016) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative...
-
Aug 3, 201613 Subjects with Basal Cell Carcinoma Nevus Syndrome Who Had 167 Surgically Eligible Target Tumors Complete 16 Weeks Dosing
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (August 3, 2016) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Jun 2, 2016
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 2, 2016) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Jun 1, 2016Funds raised will support ongoing Phase II(b) clinical trial in Basal Cell Carcinoma Nevus Syndrome, an orphan cancer hereditary disease requiring life-long therapy with no approved pharmaceutical treatment
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 1, 2016) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Sep 29, 2015Sites scheduling additional patients in HPPI’s study of proposed treatment for basal cell carcinoma nevus syndrome
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (September 29, 2015) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Aug 21, 2015Enrollment commenced in HPPI’s Phase II(b) study of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – August 21, 2015 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
May 18, 2015HedgePath to shortly commence Phase II(b) skin cancer trial using Mayne Pharma’s SUBATM-Itraconazole
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (May 18, 2015) – HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Dec 16, 2014HPPI to commence Phase IIb study in first quarter 2015 of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – December 16, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Nov 18, 2014Company plans to commence clinical development of SUBA®-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome
FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – November 18, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...
-
Jun 26, 2014Stefan Cross, Dr. Dana Ono and Mark Watson add significant biotechnology, capital markets and public accounting expertise to HPPI’s board of directors
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 26, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Jun 25, 2014$1.5 million in proceeds to fund 2014 commencement of HPPI’s clinical development program for repurposing the approved anti-fungal drug itraconazole for the treatment of cancer, initially for the treatment of Basal Cell Carcinoma Nevus Syndrome
FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 25, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...
-
Jan 8, 2014Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (January 8, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...
-
Sep 10, 2013Acquires Exclusive U.S. Rights for use of Mayne Pharma’s SUBA™ Itraconazole for treatment of cancer
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (September 10, 2013) – HedgePath Pharmaceuticals, Inc. (OTCPink:HPPI) (HPPI) announced today that it has signed an exclusive Supply and License...
-
Aug 9, 2013Commences Trading on the OTC Pink Market Under the Symbol “HPPI”
TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA -- (August 19, 2013) – HedgePath Pharmaceuticals, Inc. (OTCPink:HPPI) (HPPI) announced today that it has completed a series of transactions to effectuate...